

2011 Conference Program

SUNDAY 16 OCTOBER

8:00am – 7:00pm	DELEGATE REGISTRATION DESK OPEN <i>Concourse, Adelaide Convention Centre</i>
9:00am – 5:00pm	SATELLITE EVENTS 9:00am – 4:30pm BioBasics in one day - Industry knowledge for the non-scientist <i>Meeting Room 5, Adelaide Convention Centre</i> Separate registration required, further information at www.ausbiotech.org/bioprocourses 9:00am – 5:00pm MBA in a Day – Business basics for the bioscientist course <i>Meeting Room 4, Adelaide Convention Centre</i> Separate registration required, further information at www.ausbiotech.org/bioprocourses 9:00am – 4:30pm Smart IP Management – Putting the IP Manual into Practice <i>Meeting Room 6, Adelaide Convention Centre</i> Separate registration required, further information at www.ausbiotech.org/bioprocourses
11:00am – 4:00pm	Davies Collison Cave's - South Australian food and wine experience Travel through some of South Australia's renowned wine regions stopping along the way and including a sumptuous lunch at one of the wineries. Tour departing Sunday 16 October at 11am from The Adelaide Convention Centre and returning to Adelaide at 4pm.
12:30pm – 4:30pm	One 2 One BioServices Hospira Facility Tour Tour of Hospira's Facility, with lunch provided and optional tour onto Adelaide Botanical Gardens. Tour departing Sunday 16 October at 12.30pm from the Adelaide Convention Centre and returning by 4:30pm
2:15pm – 3:45pm	To Feed or to Fuel - How, is the question <i>Riverbank Room 1 & 2</i> BioSA proudly presents a public forum www.bioinnovationsa.com.au/events/public-forum-to-feed-or-to-fuel-how-is-the-question
4:15pm – 5:30pm	Queensland Government VIP Reception <i>Riverbank Room 3</i> By Invitation Only
5:30pm – 6:00pm	Delegates to make their way to the Adelaide Oval for the Welcome Reception BioSA hosts will be at the front of the Adelaide Convention Centre (North Terrace) and will guide Delegates onto bus shuttle leaving periodically or opt for a short stroll to take in the sights of historic North Terrace en route to Adelaide Oval.

2011 Conference Program

Table of Contents

Welcome Messages

Venue Information

Event Partners

AusBiotech Information

Plenary Speaker Profiles

Conference Program

Chairs & Speakers

Networking / Social Events

BioIndustry Exhibition

6:00pm – 7:30pm	BIOSA WELCOME RECEPTION FOR AUSBIOTECH 2011 including presentation of the BioSA Awards For registered delegates only – all Delegates to wear their Delegate Passes as tickets for entry. <i>Adelaide Oval – Richardson Gates, North Adelaide</i> Sponsored by BioSA
-----------------	--



MONDAY 17 OCTOBER	
7:15am – 8:30am	KPMG R&D Tax Credit Workshop <i>Riverbank Room 2</i> Cutting through complexity: R&D breakfast symposium For more information or to register your attendance contact Jo Nguyen on 03 9838 4444 or jonguyen@kpmg.com.au Speaker: Alan Garcia, Partner, KPMG <i>"New R&D Tax Incentive - Opportunities and pitfalls, including analysis of rules regarding: grouping, feedstock, clawback, and overseas expenditure."</i>
8:00am – 5:30pm	BIOINDUSTRY EXHIBITION HALL OPEN TO ALL DELEGATES
9:00am – 11:00am	OPENING OF AUSBIOTECH 2011 <i>Hall E, Adelaide Convention Centre</i> AusBiotech 2011 to be officially opened by The Hon Jay Weatherill MP, Minister for Science and Information Economy, South Australia & Dr Anna Lavelle, Chief Executive Officer, AusBiotech Ltd
	PLENARY 1 Introduction: Dr Anna Lavelle, Chief Executive Officer, AusBiotech Ltd Speaker: Dr Cathal O'Reilly, Managing Director, Centreview Partners, London <i>"Australia in the global pharma and biopharma context"</i>
	PLENARY 2 Introduction: Ian Thompson, Managing Director, Amgen Australia Speaker: Dr Willard H. Dere, Senior Vice President, International Chief Medical Officer, Amgen, USA <i>"Biotechnology Industry Faces an Explosion of Scientific Advancements and a Tsunami of Real World Challenges."</i>
	AUSBIOTECH – GSK STUDENT EXCELLENCE AWARDS – presented by Dr Deborah Rathjen, Chair, AusBiotech Ltd & Camilla Chong, Medical Director, GlaxoSmithKline Australia Sponsored by GlaxoSmithKline





2011 Conference Program

11:00am – 11:30am	Morning Tea <i>BioIndustry Exhibition Hall</i> Sponsored by Merrill Datasite
11:00am – 11:30am	INNOVATION CAFÉ OPEN TO ALL DELEGATES
11:30am – 1:00pm	MEDTECH <i>Room 2</i> The Future of Health in a Mobile world - An overview of the technology, trends and issues <p>Mobile networks now reach some 90% of the world's population and there is increasing use of smart phone based health apps and devices by consumers and healthcare workers alike. As a result, mobile technology is increasingly becoming a powerful conduit for health services that promises to provide affordable monitoring, diagnostic and information wherever the patient or physician may be.</p> <p>This session will look at the trends, technologies and issues facing the adoption and uptake of mobile health including regulatory concerns, human centred design and technology options. It will ask where the demand really is or will be, what cultural and economic challenges there are in harnessing it and who's likely to pay.</p> <p>Chair and speaker: David Blake, Co-Founder & Co- Editor, Bioshares</p> <p>Speakers: James Brennan, Business Development Manager, Design + Industry Dr Arthur Brandwood, Founder & CEO, Brandwood Biomedical Peter Lewis, GM – Business Development, Hydrix</p>
	HUMAN HEALTH <i>Room 3</i> Sino-Australian Partnerships: How Chinese and Australian companies integrate and formulate partnerships <p>China and Australia actively take part in a close and politically robust partnership since 1972. A panel of companies will discuss their strategy and business partnerships, bridging the two countries in the life sciences arena.</p> <p>Chair: Dr Robert Lee Kilpatrick, Partner, TVG LLC, United States</p> <p>Speakers: Dr Richard Soll, Senior Vice President of Integrated Services, WuXi AppTec, China Dr Peter French, Chief Executive Officer, Benitec Dr Janette Dixon, Vice President Global Business Development, QRx Pharma Limited</p>

2011 Conference Program

Table of Contents

Welcome Messages

Venue Information

Event Partners

AusBiotech Information

Plenary Speaker Profiles

Conference Program

Chairs & Speakers

Networking / Social Events

BioIndustry Exhibition

<p>11:30am – 1:00pm</p> <p><i>(Continued)</i></p>	<p>GENERAL</p> <p><i>Room 1</i></p> <p>Research as a pipeline for industry</p> <p>The pathway for research to become successfully commercialised involves facilitation from across the biotechnology sector. This panel discussion will include opinion leaders from key stakeholder groups in government and industry:</p> <p><i>IP facilitation</i> - The South Australian Chief Scientist, Prof Don Bursill will discuss policies and the importance of R&D as a pipeline for industry.</p> <p><i>Commercial facilitation</i> - CEO of BioSA Dr Jurgen Michaelis will discuss the role of state government and venture capital in fostering innovation systems and providing support mechanisms. Mr Don Ben-Meir, CEO Commercialisation Australia will give an insight in to federal government industry development support and Dr Ian Nisbet, Partner Afandin Pty Ltd will discuss from an industry perspective needs and expectations for successful commercialisation.</p> <p>Chair: Professor Michael Miller AO, Chair, ATSE SA Division & Professor Emeritus, University of South Australia</p> <p>Speakers:</p> <p>Adjunct Professor Don Bursill AM, Chief Scientist South Australia Doron Ben-Meir, CEO, Commercialisation Australia Dr Ian Nisbet, Partner, Afandin Pty Ltd Dr Jurgen Michaelis, Chief Executive Officer, BioInnovation SA</p> <p>INVESTMENT / BUSINESS</p> <p><i>Hall B</i></p> <p>Good News Stories in Australian Venture Capital</p> <p>This session will present and discuss positive news in VC in regard to Biotech and Life Sciences in 2010/2011. The panel will present and discuss positive news. This in itself will be interesting in the light of such a gloomy scene in previous news and is in line with the theme of Creativity Capability and Capital.</p> <p>Chair: Dr Mike Hirshorn, Director, Four Hats Capital</p> <p>Speakers:</p> <p>Dr Joshua Funder, Partner, GBS Venture Partners Liddy McCall, Director, Yuwa Capital Dr Paul Kelly, General Partner and Executive Director, OneVentures Pty Ltd Dr David Fisher, Managing Director, Brandon Capital Dr Mark Harvey, Partner, CM Capital Investment Pty Ltd</p>
<p>12:45pm – 2:00pm</p>	<p>Queensland Government Luncheon</p> <p><i>Riverbank Room 3, by invitation only</i></p>
<p>1:00pm – 2:00pm</p>	<p>Lunch</p> <p><i>BioIndustry Exhibition Hall</i></p>

2011 Conference Program

1:00pm – 2:00pm	INNOVATION CAFÉ OPEN TO ALL DELEGATES
2:00pm – 3:30pm	<p>AG / INDUSTRIAL / ENVIRONMENTAL</p> <p><i>Room 2</i></p> <p>The Food Security Challenge</p> <p>Chair: T Justus Homburg, Founder & Executive Director, YHI Ventures Pty Ltd</p> <p>Speakers:</p> <p>Dr Harvey Glick, Senior Director, Scientific Affairs Asia, Monsanto, Singapore</p> <p>Professor Peter Langridge, Chief Executive Officer, Australian Centre for Plant Functional Genomics, Adelaide</p> <p>Professor German Spangenberg, Executive Director, Department of Primary Industries, Biosciences Research Division</p>
	<p>HUMAN HEALTH</p> <p><i>Room 3</i></p> <p>Capability – cooperative approach to the clinical trial regulatory process</p> <p>Recent developments toward streamlining processes for the ethics and governance regulatory processes and broader initiatives to build clinical trials activity in Australia will be discussed. This session will include new capabilities in Victoria, New South Wales and Queensland and South Australia relating to single ethical review of clinical trials at multiple sites. Joint initiatives across these states will be described, including mutual acceptance and operation of an IT platform (AU RED) to provide comprehensive data on clinical trial activity. How Australia can best position to compete for global clinical trials, the challenges and improved capabilities for multi-centre clinical trials will be addressed. This collaborative approach will also support Australian pharmaceutical and biotechnology industries. The Clinical Trial Action Group (CTAG) Report will be discussed regarding future developments to attract clinical trials to Australia.</p> <p>Chair and speaker: Lisa Nelson, General Manager, Nucleus Network</p> <p>Speakers:</p> <p>Dr Suzanne Hasthorpe, Manager, Coordinating Office for Human Research Ethics, Department of Health, Victoria</p> <p>Dr Jo Mitchell, Associate Director Research, Ethics and Public Health Training, New South Wales Health</p> <p>Dr Jane Jacobs, Director, Office for Health and Medical Research, Queensland Health</p> <p>Brendan Shaw, Executive Director Health Policy and Research, Medicines Australia</p> <p>Kym Short, Clinical Project Manager, AstraZeneca</p> <p>Karen West, Senior Director Clinical Operations Asia Pacific, INC Research</p> <p>Peter Chesworth, General Manager, Department of Innovation, Canberra, ACT</p>

2011 Conference Program

Table of Contents

Welcome Messages

Venue Information

Event Partners

AusBiotech Information

Plenary Speaker Profiles

Conference Program

Chairs & Speakers

Networking / Social Events

BioIndustry Exhibition

2:00pm – 3:30pm

(Continued)

GENERAL

Room 1

Successful elements throughout a technology company life cycle

As a technology company matures it needs to adapt in order to survive and thrive in a competitive market. This session will review three key elements of a biotechnology company's life cycle: intellectual property, clinical development and commercialisation. The speakers will review key aspects of these areas, common pitfalls and how these strategies change and integrate over time. Properly executed these strategies form successful elements throughout a technology company life cycle.

Chair: Dr Anthony Filippis, Partner, Afandin Pty Ltd

Speakers:

Dr Ben Borson, President, Borson Law Group LLC, United States

Dr David Fuller, Chief Operating Officer and Chief Medical Officer, INC Research Australia

Dr Leigh Farrell, Vice President Business Development, Biota Holdings Limited

INVESTMENT / BUSINESS

Hall B

Accessing Equity Capital markets – legal and practical considerations for Australian companies seeking to raise equity capital from Australia, the US and China

This session will focus on a key challenge confronting many life sciences companies – accessing equity capital. View s will be provided by a panel of speakers with significant experience in equity capital raising regarding alternatives available to access capital from investors in Australia, the US and China. Particular considerations, challenges and opportunities available to biotechnology companies will be explored. The panel will be chaired by Baker & McKenzie Partner, Simon De Young. Simon will also speak about equity capital raising in Australia, including particular issues associated with raising capital from Chinese investors. Dr Meera Verma from Hospira will talk about her experiences regarding the life cycle of a biotechnology company – from start- up, to ASX listing, to takeover, to working within a multinational. Eric Boone, Special Counsel at Baker & McKenzie, will speak about opportunities to access the US capital markets. The fourth speaker on the panel w ill be an investment banker who w ill give the audience practical advice based on their experience with biotechnology companies raising capital in Australia.

Chair and speaker: Simon De Young, Partner, Baker & McKenzie

Speakers:

Dr Meera Verma, Director Site Operations, Hospira

Eric Boone, Partner, Baker & McKenzie

Trent Donnelly, Director Corporate Finance,

E.L & C. Baillieu Stockbroking, Australia

Sponsored by Baker & McKenzie

BAKER & MCKENZIE

2011 Conference Program

3:30pm – 4:00pm	Afternoon Tea <i>BioIndustry Exhibition Hall</i> Sponsored by ACPFG
	
3:30pm – 4:00pm	INNOVATION CAFÉ OPEN TO ALL DELEGATES
4:00pm – 5:30pm	MEDTECH <i>Room 2</i> Developing a Robust Regulatory Strategy: Setting the Stage for Success <p>Robust regulatory strategy is critical for an efficient and successful development program. Since regulatory strategy drives the nonclinical and clinical studies that are needed for registration of a device or pharmaceutical product, it should be prepared early in development so as to create a vision for what the program will be. In this session, we will review a process for preparing a regulatory strategy and seeking input from team members and regulators. We will also discuss the selection of product development team members and the strengths that each may bring to the team. The process of building of a regulatory milestone plan, complete with agency meetings will be discussed. Throughout the session, the importance of robust communication with regulators as customer will be emphasized.</p> <p>Chair and speaker: Dr William K. Sietsema, Vice President, Global Regulatory Consulting & Submissions, INC Research, United States</p> <p>Speakers: Dr Rosalie Cull, Managing Director, TudorRose Consulting Pty Ltd David Harrison, General Manager, Brandwood Biomedical Pty Ltd</p>
	HUMAN HEALTH <i>Room 3</i> Tissue Regeneration and Biomaterials <p>The application of biotechnology and tissue engineering to wound management has resulted in the development of numerous products that improve wound management. However, there are still significant opportunities for new and improved products to shorten healing times and reduce scarring. The speakers all have extensive experience in tissue bio-engineering and have had a active involvement in product development.</p> <p>Chair: Professor Stephen Prowse, CEO, CRC for Wound Management Innovation</p> <p>Speakers: Associate Professor John Greenwood, Director Burns Unit, The Royal Adelaide Hospital <i>"The development of NovoSkin"</i> Professor Robert Short, Director of the Mawson Institute, University of SA <i>"Understanding and Tailoring the Biological-Material Interface: Plasma Polymerisation for Cell Attachment and Haptotaxis"</i> Paul Brennan, Marketing Director ANZ, Healthcare Division, Smith & Nephew Pty Ltd <i>"Market drivers in wound repair and tissue regeneration"</i></p>

2011 Conference Program

<p>4:00pm – 5:30pm</p> <p>(Continued)</p> 	<p>AG / INDUSTRIAL / ENVIRONMENTAL</p> <p><i>Room 1</i></p> <p>Applications of agricultural biotechnology</p> <p>Chair: Professor Mark Tester, VP, Company Director & Co-Founder, BIOCONST Pty Limited</p> <p>Speakers:</p> <p>Dr Robyn Heath, Senior VP Product Development, Hexima Limited</p> <p>Dr Justin Coombs, Head of Agriculture, TPI Enterprises</p> <p>Cameron Turner, Innovation and Commercial Development Manager, UniQuest, University of Queensland</p> <p>Dr Juan Juttner, Manager Gene Discovery, Grains, Research and Development Corporation</p> <p>INVESTMENT / BUSINESS</p> <p><i>Hall B</i></p> <p>Recent successful trade sale exits in Australian Biotech, a continuing trend?</p> <p>At the end of the day, investors in biotech companies are generally there to make money. The speakers in this session have been the key drivers of successful trade exits in listed or private companies that have provided significant returns to shareholders. You will hear some of the secrets that made these deals possible.</p> <p>Chair and speaker: Dr Stewart Washer, Chief Executive Officer, Calzada Ltd</p> <p>Speakers:</p> <p>Matthew Callahan, Chief Executive Officer, iCeutica Inc, United States</p> <p>Dr John Chiplin, Managing Director, Newstar Ventures Ltd</p> <p>Matt McNamara, Chief Investment Officer, IB Australian Bioscience Fund</p> <p>Dr Greg Collier, Managing Director, Barwon Biotechnology</p> <p>Eugene Ong, Lead Sales Manager, Ansarada</p> <p>Sponsored by Ansarada</p> 
<p>5:30pm – 6:30pm</p>	<p>EXHIBITOR'S RECEPTION</p> <p><i>Hall H, BioIndustry Exhibition Hall – AusBiotech Booth precinct</i></p>
<p>6:30pm – 8:00pm</p>	<p>AUSBIOTECH 2011 EVENT PARTNERS RECEPTION</p> <p><i>Foyer 1</i></p> <p>Strictly by invitation only.</p>

2011 Conference Program

TUESDAY 18 OCTOBER

7:30am – 9:00am	Queensland Government International Breakfast <i>Riverbank 3</i> By Invitation only
8:00am – 5:30pm	SATELLITE EVENT AusFoodtech 2011 Symposium <i>Riverbank Room 1, Adelaide Convention Centre</i> Separate registration required at www.ausbiotech2011.com.au/AusFoodtech
9:00am – 10:00am	PLENARY 3 <i>Hall E, Adelaide Convention Centre</i> Introduction: Dr Anna Lavelle, Chief Executive Officer, AusBiotech Ltd Speaker: Dr Paul Stoffels, Worldwide Chairman, Janssen, Pharmaceutical Companies of Johnson & Johnson <i>"Patients First - New Models in Pharmaceutical R&D"</i>
10:00am – 11:00am	PLENARY 4 Millis Oration <i>Hall E, Adelaide Convention Centre</i> Overview: Dr Deborah Rathjen, Chair, AusBiotech Ltd Introduction of Millis Orator: Dr Simon Green, Senior Vice President, Global Product Development, CSL Limited Speaker: Professor Ross McKinnon, Research Director and Professor in Cancer Research, Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University <i>"Translating health discovery into clinical applications: an Australian perspective"</i> Sponsored by CSL Limited
11:00am – 11:30am	Morning Tea <i>BioIndustry Exhibition Hall</i>  Sponsored by CAS
11:30am – 1:00pm	INNOVATION CAFÉ OPEN TO ALL DELEGATES

2011 Conference Program

Table of Contents

Welcome Messages

Venue Information

Event Partners

AusBiotech Information

Plenary Speaker Profiles

Conference Program




Chairs & Speakers

Networking / Social Events

BioIndustry Exhibition

11:30am – 1:00pm	<div data-bbox="300 279 393 300">MEDTECH</div> <div data-bbox="300 311 364 331"><i>Room 2</i></div> <div data-bbox="300 339 706 360">Health Technology Assessment Implementation</div> <div data-bbox="300 368 938 435"> <p>Chair and speaker: Warren Bingham, President – Australia and New Zealand, Given Imaging, Pty Ltd <i>"The HTA Review process – what does it mean for medical devices in Australia?"</i></p> </div> <div data-bbox="300 440 384 461">Speakers:</div> <div data-bbox="300 469 745 563"> <p>Dr Sarah Norris, Co-Director, Health Technology Analysts <i>"As a medical device company, what do we need to do?"</i> Professor Brendon Kearney, Site Clinical Director RAH, Haematology, SA Pathology</p> </div> <div data-bbox="300 576 449 596">HUMAN HEALTH</div> <div data-bbox="300 606 364 627"><i>Room 3</i></div> <div data-bbox="300 636 885 683">Coding, Payment and Coverage: Emerging Issues for Drug & Device Companies Accessing North American and European Territories</div> <div data-bbox="300 692 925 828"> <p>Healthcare systems, particularly those in the US are undergoing significant change as the introduction of the Obama healthcare reforms cut in. The pressures on pricing and cost containment will increase, possibly forcing major adjustments at the product origination end of the value creation chain. What can small companies learn from mature companies (as represented by the speakers) as they navigate the coding, payment and coverage pathways?</p> </div> <div data-bbox="300 839 925 861">Chair: Shane Storey, Senior Research Analyst, Wilson HTM Investment Group</div> <div data-bbox="300 873 384 893">Speakers:</div> <div data-bbox="300 901 801 949"> <p>Paul MacLeman, Chief Executive Officer, Genetic Technologies Michael Wonder, Wonder Drug Consulting</p> </div> <div data-bbox="300 970 389 991">GENERAL</div> <div data-bbox="300 1000 364 1021"><i>Room 1</i></div> <div data-bbox="300 1031 876 1077">Sourcing capital? Improve your investment readiness and valuation through better IP management</div> <div data-bbox="300 1086 936 1224"> <p>Intellectual property rights are a key asset for any biotech company. However for the many Australian biotech companies that will never sell a tangible product, their IP portfolio is by far the most important component of shareholder value. Where the return to a company's investors will be generated through a pre-revenue trade sale, or via a licence or other partnering deal, the company's 'product' is, in effect, its IP portfolio.</p> </div> <div data-bbox="300 1232 925 1324"> <p>Investors favour companies whose IP management is integrated with the company's business strategy, and with its R&D planning - where IP is seen as a core business asset, not as a legal add-on. So how does one demonstrate a soundly based, well-integrated IP strategy to potential investors?</p> </div> <div data-bbox="300 1332 835 1423"> <p>Let this panel of respected industry leaders identify key factors that investors consider when evaluating potential investment opportunities, and how proactive IP management can both enhance your value proposition as well as safeguarding your own investment.</p> </div>
------------------	--

2011 Conference Program

<p>11:30am – 1:00pm</p> <p>(Continued)</p> <p> DIBBSBARKER</p>	<p>GENERAL (cont.)</p> <p><i>Room 1</i></p> <p>Sourcing capital? Improve your investment readiness and valuation through better IP management</p> <p>Chair: Glenn Cross, Chief Operating Officer, AusBiotech Ltd</p> <p>Speakers:</p> <p>Ian Lewis, Director, SAMIAN Underwriting, United Kingdom</p> <p>Dr Rob Crombie, Managing Director, Concept2ClinicConsulting</p> <p>Rob McInnes, Partner, Intellectual Property and Technology, Dibbs Barker</p> <p>Michael Quinn, Managing Partner, Innovation Capital</p> <p>Sponsored by Dibbs Barker and Willis Australia</p> 
	<p>INVESTMENT / BUSINESS</p> <p><i>Hall B</i></p> <p>Transpacific Biotech Capital: Case Studies Sourcing Human and Financial Capital for Biotech</p> <p>For late stage biotechnology product development, deep pockets are needed. In addition to financial capital, international syndication also brings access to deeper pools of human capital and exit opportunities. Increasingly, successful late stage biotech companies in Australia have attracted and deployed both US and Australian capital to develop global products. This panel session sets out to explore and explain multiple models of transpacific financing from venture syndicates through PIPES to corporate partnerships.</p> <p>Chair: Dr Joshua Funder, Partner, GBS Ventures</p> <p>Speakers:</p> <p>Dr Alan Robertson, Chief Executive Officer Pharmaxis "US-AU public investor register"</p> <p>Dr Anthony Sun, Partner, Aisling Capital, United States "US- based venture and/or public markets investor"</p> <p>Dr Richard Treagus, Chief Executive Officer, Acrux "US-AU pharma partnership and financing"</p> <p>Dr Greg Collier, Managing Director, Barwon Biotechnology "US-AU PIPE"</p> 
<p>1:00pm – 2:00pm</p>	<p>AUSBIOTECH LTD ANNUAL GENERAL MEETING</p> <p><i>Meeting Room 5, Adelaide Convention Centre</i></p> <p>All AusBiotech members are encouraged to attend and participate at the Annual General Meeting.</p>
<p>1:00pm – 2:00pm</p>	<p>Lunch</p> <p><i>BioIndustry Exhibition Hall</i></p>
<p>1:00pm – 2:00pm</p>	<p>INNOVATION CAFÉ OPEN TO ALL DELEGATES</p>

2011 Conference Program

Table of Contents

Welcome Messages

Venue Information

Event Partners

AusBiotech Information

Plenary Speaker Profiles

Conference Program

Chairs & Speakers

Networking / Social Events

BioIndustry Exhibition

2:00pm – 3:30pm

HUMAN HEALTH

Room 3

Development of Biopharmaceuticals in Australia: Pathways to Success in a Global Setting

Identification of the right partners is critical to the success of a biopharmaceutical product. The panel will address critical steps for selection of the right partners. Communication between the parties involved and alignment of the planning is crucial for a successful project. Australian service providers on the panel will illustrate how financing, regulatory support, clinical trial design and process development/cGMP manufacturing contribute to the development programs of Australian biopharmaceutical companies. A view from the biopharmaceutical companies side will round the picture.

Chair: David Hughes, Chief Executive Officer, BioPharmaceuticals Australia

Speakers:

Anne-Maree Keane, Partner, Transaction Advisory Services, Ernst & Young
Terry Hurst, Chief Executive Officer, Q-Pharm Pty Ltd
Dr Dianne Jackson-Matthews, Director of Regulatory Affairs, ERA Consulting
Robert Gay, Director Manufacturing, Cephalon Australia Pty. Ltd.
Marc Goemans, Senior Director New Business Development Asia – Pacific, DSM Biologics, Netherlands

Sponsored by DSM Biologics, Netherlands



GENERAL

Room 1

IP Reform in Australia: A Health & Status Check

IP Reform in Australia: A Health & Status Check will feature leading biopharma Intellectual Property specialists, from industry and service providers, who will discuss and workshop the recent Australian IP reform initiatives relevant to biopharma players, including:

- Patent reform;
- ACIP report, Gene Patenting and patentable subject matter; and
- Copyright in PIs.

This session will outline and workshop the IP reform initiatives from technical and practical perspectives, always addressing the effect of the proposed reforms on industry.

Chair: Dr Tim Oldham, Corporate Vice President and President, Asia Pacific, Hospira Inc.

Speakers:

Naomi Pearce, IP Director & Counsel, Hospira Australia Pty Ltd
Kim O'Connell, Partner, Mallesons Stephen Jaques
Dr Jenny Petering, Partner, FB Rice
Dr Kristy McCamley, Intellectual Property Manager & Patent Attorney, Research, Biota Holdings Limited

Sponsored by Hospira



2011 Conference Program

2:00pm – 3:30pm <i>(Continued)</i>	INVESTMENT / BUSINESS <i>Hall B</i> International Investors Unplugged <p>An interactive forum designed to enable management teams to query venture and public investors from Australia, Europe and the U.S. The goal of this session is to encourage dialogue and promote candid, informal conversation between management teams and portfolio managers.</p> <p>Chair: Hershel Berry, Managing Partner, Blueprint Life Sciences, United States</p> <p>Speakers: Clarke Futch, Managing Director, Cowen Healthcare Royalty Partners, United States Lawrence Gozlan, Chief Executive Officer, Scientia Capital, Australia Dr Ron Laufer, Managing Director, MedImmune Ventures, United States Dr William Shen, Partner, Venbio, United States Joe Sum, Vice President, Biotechnology Value Fund, United States Dr Anthony Sun, Partner, Aisling Capital United States</p>
2:30pm – 5:30pm	AUSBIOTECH 2011 TRADE AFTERNOON <i>BioIndustry Exhibition Hall</i> <p>The AusBiotech BioIndustry Exhibition is the largest biotechnology exhibition assembled in Australia. The exhibition showcases the latest in business and product services, equipment, instrumentation, devices and state-of-the-art technology. The Trade Afternoon is offered in addition to general access of the BioIndustry Exhibition for exhibitors and delegates. This time has been allocated specifically for exhibitors to invite guests and for graduate and undergraduate students to attend and engage with industry.</p>
3:30pm – 4:00pm	Afternoon Tea <i>BioIndustry Exhibition Hall</i>
3:30pm – 4:00pm	INNOVATION CAFÉ OPEN TO ALL DELEGATES
4:00pm – 5:30pm	AG / INDUSTRIAL / ENVIRONMENTAL <i>Room 1</i> Biotechnology in winemaking: adding value to a 7000 year old product <p>Chair: Dr Mark Krstic, President of the Australian Society of Viticulture and Oenology</p> <p>Speakers: Dr Ian Dry, Principal Research Scientist, CSIRO's Plant Industry Division <i>"Biotechnology in the vineyard. New technologies for disease resistant varieties."</i> Professor Sakkie Pretorius, Managing Director, The Australian Wine Research Institute <i>"Wine yeast: Searching for novel answers in A's, C's, G's and T's."</i> Patricia Osidacz, Senior Sensory Scientist, The Australian Wine Research Institute <i>"Consumer and sensory science, including the influence of human genetics on sensory perception in wine."</i></p>

2011 Conference Program

Table of Contents

Welcome Messages

Venue Information

Event Partners

AusBiotech Information

Plenary Speaker Profiles

Conference Program

Chairs & Speakers

Networking / Social Events

BioIndustry Exhibition

4:00pm – 5:30pm

(Continued)

HUMAN HEALTH

Room 3

Clever cell culture for the innovation of biologics

Cell culture is a critical technological capability in the research, development, and production of new biologics and therapeutics. This session will discuss the use and application of cell culture to the development of new biologics and therapeutics, from initial research and development through to large scale production. In particular, it will concentrate on some of the challenges of cell culture, with the aim of building knowledge and capability within the industry. Topics to be discussed include cell line establishment, cell line cross-contamination and infection, process optimization, production scale-up, and the production and purification of recombinant proteins.

Chair and speaker: Dr Jonathan Arthur, General Manager, CellBank Australia
"Simple strategies for reducing the risks of cell line contamination"

Speakers:

Dr George Lovrecz, Head of Fermentation Group,
 Material Science and Engineering, CSIRO
"Process versus Product Optimisation"

Prof Roger Reddel, Director, Children's Medical Research Institute
"Immortalisation of human cells"

Dr Verna McErlane, Director of Commercial Operations International,
 Sismic, Scotland
*"The challenges of advancing stem cell therapies
 into the clinic: a characterisation perspective"*

GENERAL

Room 2

Biomanufacturing

Germany's biomanufacturing sector is known worldwide as one of the industry's leaders. With a fermentation capacity of 675,000 liters, Germany leads Europe and is second only to the US in the production of biopharmaceuticals.

Representatives from leading German companies Rentschler and Boehringer Ingelheim Pharma will participate in a panel discussion together with representatives from two of Australia's leading companies in biomanufacturing CSL and Hospira.

The companies will discuss their capabilities, achievements and latest technology developments. Discussion will also include the development of export initiatives for the German health care industry, as well as the creation of a "German Biomanufacturing Guide".

Chair: Dr Jurgen Michaelis, Chief Executive Officer, BioInnovation SA

Speakers:

Dr Anne Collins, Associate Director One 2 One Biosciences, Hospira Adelaide

Hans-Peter Grau, Vice President Business Development,
 Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

Dr Klaus B. Schoepe, Senior Vice President Client Relations,
 Rentschler Biotechnologie, Germany

Dr Simon Green, Senior Vice President Global R&D
 Product Development, CSL Limited



2011 Conference Program

4:00pm – 5:30pm <i>(Continued)</i>	INVESTMENT / BUSINESS <i>Hall B</i> Partnering and other non equity diluting strategies <p>With capital markets drying up, unlisted and listed biotechs need to be creative in terms of capital to fund their business. "Working capital" developed through revenue generation activities is becoming increasingly important for small biotechnology. Revenue generating partnerships with other biotechs and pharma companies provides an alternative to a dilutive capital raising while further developing and validating the technology. Strategic partnering is now an essential part of the business model for many biotech companies and companies need to develop the appropriate set of relationships as early as possible during their development. This business model is most beneficial to platform companies, where frequent partnering validates the technology, provides cash for growth and may be a sustainable business in its own right.</p> <p>Chair: Dr Mark Ashton, Manager, Innovation and Commercial Development, Uniquist</p> <p>Speakers: Samantha Cobb, Chief Executive Officer, AdAlta Pty Ltd Dr Esra Ogru, Chief Executive Officer, Phosphagenics Dr Alexandra Tickle, Commercialisation Manager, Otago Innovation, New Zealand Dr Stella Xu, Regional Head, Greater China and Southeast Asia, Roche Partnering, Shanghai, China Nick Woolf, CFO VP Corporate Development, Phylogica Ltd</p>
5:30pm – 6:30pm	UKTI Exhibitor Function Strictly by invitation only.
7:00pm – 11:30pm	AUSBIOTECH 2011 CONFERENCE DINNER <i>Hall F, Adelaide Convention Centre</i> <p>Pre dinner drinks in the foyer from 7pm – All attendees must have a Dinner Ticket for entry to the official Conference Dinner.</p> <p>Sponsored by Pfizer</p>

WEDNESDAY 19 OCTOBER

8:30am – 5:30pm	AUSTRALASIAN LIFE SCIENCE INVESTMENT SUMMIT 2011 <i>Hall E, Adelaide Convention Centre</i> <p>Attendance strictly by invitation only – further information www.ausbiotech2011.com.au/alsis</p> <p>Delegates to the AusBiotech 2011 conference will for the first time have access to auditorium seating at the rear of the presentation hall to be able to listen to 40 of the top Private and ASX listed life science companies.</p> <p>Sponsored by Australian Securities Exchange, Blueprint Life Science Group, CSL Limited, RBS Morgans and South Australian Government</p> <p>Program outlines for the Summit will be available at the Summit Registration Desk outside Hall E.</p>
-----------------	---

2011 Conference Program

9:30am – 11:00am	<p>MEDTECH <i>Room 2</i> Diagnostics and their place in the world</p> <p>Early and effective diagnosis of disease is critical to better manage treatments for patients and ever-increasing healthcare costs. With a burgeoning world population and escalating immigration rates resulting in widespread occurrence and rapid spread of disease, diagnostic solutions need to address global healthcare needs. This requires innovation for the development of technologies and products that are appropriate for different settings and can be supported by the infrastructure and work flows in developing and emerging nations, as well as in developed countries.</p> <p>The emphasis of this session is on the development of new in vitro diagnostic technologies that offer improved performance at low cost and ease of use for deployment in low and middle income countries. These are referred to as “disruptive” or “reverse” innovation technologies because if they successfully provide high performance, low cost delivery in a demanding environment they have the competitive advantages to have a major impact in the developed countries.</p> <p>Chair: Dr Jenny Harry, Chief Executive Officer & Managing Director, Tyrian Diagnostics Limited</p> <p>Speakers: Dr Geoff Cumming, Chief Executive Officer, Anteo Diagnostics Andreas Knack, Director of Biomedical Instruments and Devices, Invetech <i>“Opportunities for IVD Companies in the Developing World”</i> Dr Graeme Woodrow, Director, Health Technologies Strategy, CSIRO <i>“Health Diagnostics for Developing Countries”</i></p> <p>AG / INDUSTRIAL / ENVIRONMENTAL <i>Room 1</i> Alternative Fuels</p> <p>Chair: Dr Susan Pond, Dow Sustainability Program, United States Studies</p> <p>Speakers: Nicole Williamson, Senior Technology Manager, Sustainable Aviation Fuel, Boeing Research and Technology - Australia Geoff Bell, Chief Executive Officer, Microbiogen Pty Ltd Associate Professor Ben Hankamer, Institute for Molecular Bioscience, University of Queensland Professor Rocky De Nys, School of Marine and Tropical Biology, James Cook University</p>
11:00am – 11:30am	<p>Morning Tea <i>BiolIndustry Exhibition Hall</i></p>
11:10am – 11:30am	<p>INNOVATION CAFÉ OPEN TO ALL DELEGATES</p>

2011 Conference Program

11:30am – 1:00pm

GENERAL

Room 1

Sudden Impact. Effective company branding for Australian biotechs.

First impressions are lasting impressions – this adage applies just as well to biotech companies as it does to individuals. Despite this, many Australian biotech companies don't invest sufficient effort in developing their public impression – their BRAND - to do justice to the value of their technology. This presentation will describe the key features of an effective company brand in the biotech space and provide guidelines to ensure that all a company's outward communication vehicles – presentations, website and other media consistently convey the same, accurate and positive message. Case studies of successful (and less successful) branding will be presented to illustrate the principles described. Attendees will leave the workshop with an understanding of how to measure the effectiveness of their company's brand and a clear understanding of how to make improvements, if necessary.

Speakers:

Ned Coten, Managing Director, Acorn Brand Design
Dr Alex Szabo, Principal, Golden Gate Life Sciences Partners
Becky Hyde, Chief Marketing Officer, Horizon Science



AG / INDUSTRIAL / ENVIRONMENTAL

Room 2

Animal productivity and the new genetics

This session will explore the application of new genetic technologies in agriculture. There's always been a frustration that new technologies seem difficult to get through to where the rubber hits the road in this arena. Reasons often given include the complexity of using the data, the difficulty of maintaining perfect records, and the intangible nature of "genetic superiority" to a farmer. This session will explore those issues with speakers from the different perspectives of the R&D organisation, and the commercialiser and end-user. It is sure to provide an excellent forum for audience participation and debate.

Chair: Dr Andrew Kelly, Executive Director, BioPacific Ventures, New Zealand

Speakers:

Dr Kishore Prayaga, Product Development Manager (ANZ), Pfizer Animal Genetics, Pfizer Australia Inc.
Terry Longhurst, Manager Strategic Science, Livestock Production Innovation, Meat & Livestock Australia
"Biotechnology for Genetic Improvement: A Producer Perspective"



1:00pm – 2:30pm

AUSBIOTECH 2011 CLOSING RECEPTION and WELCOME TO AUSBIOTECH 2012

BioIndustry Exhibition Hall